Rift valley fever cost-effectiveness of therapy

Jump to navigation Jump to search

Rift valley fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Rift valley fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rift valley fever cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rift valley fever cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rift valley fever cost-effectiveness of therapy

CDC on Rift valley fever cost-effectiveness of therapy

Rift valley fever cost-effectiveness of therapy in the news

Blogs on Rift valley fever cost-effectiveness of therapy

Directions to Hospitals Treating Rift valley fever

Risk calculators and risk factors for Rift valley fever cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aakash Hans, MD[2]

Overview

Although there are no first line drugs recommended for the treatment of Rift valley fever, the economic impact of the disease requires some measures to be taken to curb its spread. Vaccinating the livestock may play a significant role in decreasing human exposure and limiting the spread of infection to other healthy animals.

Cost-effectiveness of therapy

  • Vaccinating the livestock animals like goats and sheep a couple of years prior to the outbreak of RVF cases may be tremendously cost-effective to the health organizations catering to the public.
  • These benefits could be measured in terms of DALYs (disability adjusted life years) and the amount of money it costs to treat human cases.[1]
  • Improved numbers of vaccinated livestock will further improve overall cost-effectiveness.
  • Increasing surveillance for suspicious symptoms in animals will also help health organizations to react in time and decrease human contact with these infected animals to a minimum.
  • Another strategy of implementing vaccination for all livestock at baseline for periods when there is no outbreak of RVF, followed by another shot of vaccination when cases begin to rise may be used by governments to effectively curb the spread of the disease.

References

  1. Kimani T, Schelling E, Bett B, Ngigi M, Randolph T, Fuhrimann S. Public Health Benefits from Livestock Rift Valley Fever Control: A Simulation of Two Epidemics in Kenya. Ecohealth. 2016;13(4):729-742. doi:10.1007/s10393-016-1192-y

Template:WH Template:WS